Form 4: Armata Pharma Exec Receives 109,885 Stock Options

David Duane House, SVP of Finance and PFO at Armata Pharmaceuticals, was granted 109,885 stock options with a vesting schedule tied to continuous service.

Summary

• David Duane House, SVP, Finance, and PFO of Armata Pharmaceuticals, Inc. (ARMP), was granted 109,885 stock options.
• The transaction date for the grant was March 9, 2026.
• The exercise price for these options is $11.61 per share.
• The options have an expiration date of March 9, 2036.
• The vesting schedule dictates that 25% of the options will vest on March 9th of 2027, 2028, 2029, and 2030, contingent on continuous service.
• The filing indicates the transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily reflecting standard executive incentive practices and alignment of interests, rather than a direct indicator of company performance.

Positives

• The grant of stock options aligns the interests of SVP, Finance, and PFO David Duane House with those of shareholders, incentivizing long-term performance.
• The use of a Rule 10b5-1(c) plan indicates a pre-planned transaction, which can reduce concerns about opportunistic insider trading.

Negatives

• No direct negatives are presented in this Form 4 filing, as it is a disclosure of an executive compensation event.

Risks

• The vesting of options is subject to continuous service, meaning the executive must remain employed by Armata Pharmaceuticals through the vesting dates to realize the full benefit.
• The value of the options is dependent on the future stock price of Armata Pharmaceuticals exceeding the exercise price of $11.61.

Future Outlook

The vesting schedule for the stock options extends through March 2030, indicating an expectation of continued service from David Duane House and a long-term incentive structure.

Industry Context

StockSavvy.ai notes that granting stock options to senior executives is a standard practice across the biotechnology and pharmaceutical industries. This mechanism is widely used to align executive compensation with long-term shareholder value creation and to retain key talent.

Comparison to Industry Standards

• Executive stock option grants are a common component of compensation packages in growth-oriented sectors like biotech.
• While the specific number of options and exercise price are company-specific, the structure of a multi-year vesting schedule is consistent with industry benchmarks for incentivizing long-term executive performance and retention, similar to practices seen at companies like Moderna or BioNTech for their senior leadership.

Corporate Governance

Related Party Transactions

• This filing details an executive compensation event, specifically the grant of 109,885 stock options to David Duane House, a senior officer (SVP, Finance, and PFO) of Armata Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: The grant of options aims to align executive incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is noted, but it highlights the compensation structure for senior leadership.

Next Steps

• Vesting of 25% of the stock options on March 9, 2027, subject to continuous service.
• Subsequent vesting of 25% on March 9, 2028, March 9, 2029, and March 9, 2030, each subject to continuous service.

Key Dates

Keywords

Armata Pharmaceuticals, ARMP, Stock Options, Executive Compensation, Insider Transaction, Form 4, David Duane House, Rule 10b5-1